Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.71 |
| ▸ | ATR | Q13535 | 7/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16425221 | 0.90 | KCNH2 (0.70) | KCNH2ATRHPGDCHEK1 | |
| SCHEMBL2934913 | 0.89 | ATR (0.67) | KCNH2ATRHPGDLRRK2 | |
| SCHEMBL2934243 | 0.89 | KCNH2 (0.63) | KCNH2ATRHPGDCHEK1 | |
| SCHEMBL15201341 | 0.87 | KCNH2 (0.79) | KCNH2ATRHPGD | |
| SCHEMBL2932858 | 0.87 | KCNH2 (0.58) | KCNH2ATRHPGDCHEK1LRRK2 | |
| SCHEMBL2934236 | 0.87 | KCNH2 (0.72) | KCNH2ATRMKNK1MKNK2CHEK1 | |
| SCHEMBL2932374 | 0.86 | KCNH2 (0.68) | KCNH2ATRHPGDMAPK1LRRK2 | |
| SCHEMBL16425222 | 0.86 | KCNH2 (0.74) | KCNH2ATRHPGDCHEK1LRRK2 | |
| SCHEMBL2928695 | 0.86 | KCNH2 (0.55) | KCNH2ATRMKNK1MKNK2HPGD | |
| SCHEMBL2925588 | 0.86 | LRRK2 (0.56) | KCNH2ATRCHEK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | KCNH2 1056/4885ATR 556/4885MKNK1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.